Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Transient Ischemic Attack l: Introduction01:26

Transient Ischemic Attack l: Introduction

A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Fibrinogen on Tenecteplase Treatment in Acute Ischaemic Stroke After 4.5 Hours of Symptom Onset: A Post Hoc Analysis of the TRACE-III Trial.

Neurology and therapy·2026
Same author

Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial.

JAMA·2026
Same author

RNS60 RESCUE Trial in Acute Ischemic Stroke: Post Hoc Analysis in Participants Enrolled <12 Hours Since Last Known Well.

Stroke (Hoboken, N.J.)·2026
Same author

Intra-Arterial Thrombolytic vs. Mechanical Thrombectomy in Distal Medium Middle Cerebral Artery Acute Ischemic Stroke: A Preliminary Multinational Multicenter Propensity Score-Matched Study.

Clinical neuroradiology·2026
Same author

Infarct growth rate and tenecteplase benefit in ischemic stroke at 4.5 to 24 h without thrombectomy-A secondary analysis of the TRACE-III randomized trial.

International journal of stroke : official journal of the International Stroke Society·2026
Same author

Antithrombotic strategies for the secondary prevention of stroke: A review.

The American journal of medicine·2026
Same journal

Efficacy and safety of clopidogrel and aspirin initiated within 72 hours after mild ischemic stroke or high-risk TIA by sex: a prespecified subgroup analysis of the INSPIRES trial.

Expert review of cardiovascular therapy·2026
Same journal

Approaches to transcatheter aortic valve replacement failure: is more focus on prevention required?

Expert review of cardiovascular therapy·2026
Same journal

Vericiguat for heart failure with reduced ejection fraction: a perspective from approval to real-world clinical treatment.

Expert review of cardiovascular therapy·2026
Same journal

Early autonomic neuropathy in prediabetes: an overlooked driver of cardiometabolic risk.

Expert review of cardiovascular therapy·2026
Same journal

Contemporary approach and key considerations to asymptomatic aortic stenosis treatment.

Expert review of cardiovascular therapy·2026
Same journal

Giant cell myocarditis or sarcoidosis? Time to develop clinically driven non-invasive decision algorithms in inflammatory myocardial diseases: integrating clinical features, biomarkers and multimodality imaging.

Expert review of cardiovascular therapy·2026
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Acute ischemic stroke therapy.

Nils Henninger1, Rajat Kumar, Marc Fisher

  • 1Department of Neurology, University of Massachusetts Medical Center, 55 Lake Avenue, North Worcester, MA 01655, USA. nils.henninger@umassmemorial.org

Expert Review of Cardiovascular Therapy
|October 13, 2010
PubMed
Summary
This summary is machine-generated.

Tissue plasminogen activator improves outcomes for acute stroke patients within 4.5 hours. Future research aims to extend this treatment window using advanced imaging techniques for better patient selection and stroke therapy.

More Related Videos

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

Related Experiment Videos

Last Updated: Jun 8, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Emergency Medicine

Background:

  • The European Cooperative Acute Stroke Study (ECASS) III trial established tissue plasminogen activator (tPA) efficacy up to 4.5 hours post-stroke.
  • Intra-arterial therapies are used off-label beyond 4.5 hours, but lack definitive evidence.
  • Current guidelines recommend blood pressure and glucose management, and statin use for non-cardioembolic strokes.

Purpose of the Study:

  • To review current acute stroke therapies and identify future directions.
  • To highlight the need for extending the therapeutic time window for stroke treatment.
  • To emphasize the role of advanced imaging in patient selection for extended treatment.

Main Methods:

  • Review of data from the ECASS III trial.
  • Discussion of current clinical practices and evidence gaps in acute stroke management.
  • Exploration of emerging imaging modalities for patient selection.

Main Results:

  • tPA administration within 4.5 hours of stroke onset significantly improves patient outcomes.
  • Evidence for the efficacy of therapies beyond 4.5 hours remains inconclusive.
  • Imaging-guided patient selection is crucial for expanding therapeutic time windows.

Conclusions:

  • Extending the therapeutic window for acute stroke is a primary goal.
  • Advanced imaging techniques like diffusion/perfusion MRI and CT perfusion are vital for identifying suitable patients for extended treatment.
  • Increased patient access to timely stroke treatment within established windows is essential.